ClearPoint Neuro Q1 2024 GAAP EPS $(0.16) Beats $(0.19) Estimate, Sales $7.639M Beat $6.994M Estimate
ClearPoint Neuro Q1 2024 GAAP EPS $(0.16) Beats $(0.19) Estimate, Sales $7.639M Beat $6.994M Estimate
ClearPoint Neuro 2024年第一季度GAAP每股收益美元（0.16美元）超過預期（0.19美元），銷售額763.9萬美元超過預期的69.94萬美元
ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 30.43 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $7.639 million which beat the analyst consensus estimate of $6.994 million by 9.23 percent. This is a 40.60 percent increase over sales of $5.433 million the same period last year.
ClearPoint Neuro（納斯達克股票代碼：CLPT）公佈的季度虧損爲每股0.16美元，比分析師普遍預期的0.19美元（0.19美元）高出15.79％。這比去年同期每股虧損0.23美元（0.23美元）增長了30.43％。該公司公佈的季度銷售額爲763.9萬美元，比分析師普遍預期的699.4萬美元高出9.23％。這比去年同期的543.3萬美元的銷售額增長了40.60％。